OMIDRIA Special Ep. 5 OMIDRIA Pearls from AECOS 2023

Bios:

Dr Inder Paul Singh (host)

Dr Inder Paul Singh president of The Eye Centres of Racine & Kenosha Ltd. in Wisconsin. His clinical research has been published and presented at various national meetings and universities around the world. Dr. Singh was also named America’s Best Eye Doctor in 2021 by Newsweek.

Dr Arjan Hura (guest)

Dr Arjan Hura is a refractive cataract and anterior segment surgeon at the Maloney-Shamie Vision Institute in Los Angeles, California.

Dr Karolinne Rocha (guest)

Dr Karolinne Rocha is assistant Professor of Ophthalmology at MUSC in Charleston, South Carolina specializing in cataract, cornea, and refractive surgery.

 

Summary:

Dr Paul Singh is joined by Dr Arjan Hura and Dr Karolinne Rocha at AECOS 2023 in Deer Valley to discuss why they are adopting OMIDRIA. They touch a multitude of topics including the importance of maintaining pupil stability, accessibility to the medication, patient selection, and patient experience.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

This podcast is provided for general information purposes only. The presenters’ views are their own. Nothing contained within this podcast is intended to offer medical advice for the treatment of any illness or disease, nor is it a substitute for professional medical advice, diagnosis or treatment. Nothing presented in this podcast is intended to give instruction or guidance on the use of any Rayner products; it is not designed to replace a surgeon’s independent judgement about the appropriateness or risks of a procedure for a given patient. Rayner does not endorse off-label use. Users must refer to the product labelling and instructions for use for Rayner products in all cases.

Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner. © 2023 Rayner Group, all rights reserved. US-OM-2300041 11/23

 

Key Takeaways:

  • An optimized combination: OMIDRIA combines phenylephrine and ketorolac to calm inflammation and maintain pupil size during surgery.
  • A game changer: Dr. Karolinne Rocha explains that OMIDRIA has been a game changer in her practice and specifically for patients with floppy iris syndrome and for femtosecond laser cases.
  • Rapid results: When Dr. Arjan Hura started using OMIDRIA, he noticed less anterior chamber inflammation and less postoperative edema. Patients were seeing and reading better after just one day post-op.
  • Building confidence: Paul Singh highlights the fact that he is more confident during surgery with OMIDRIA. He uses less pupil expansion devices and has improved overall efficiency while decreasing surgical times.
  • Decreasing the drop burden: Hura and Dr. Singh agree that having OMIDRIA on board decreases post-op inflammation and has reduced patients’ drop regimen after surgery.
  • Improving patient experience: As Dr. Hura explains, moving towards a dropless future can increase overall patient experience by reducing stress related to following complicated drop regimens and reducing callbacks and time at post-op appointments..
  • Accessibility for (almost) all: OMIDRIA is easily accessible for the majority of patients and is now covered separately through 2028. Dr. Singh, Dr. Hura, and Dr. Rocha all note that they use it on almost every patient.

OMIDRIA Podcasts are for the attention of USA HCPs only. OMIDRIA is distributed by Rayner Surgical Inc.

 

IMPORTANT SAFETY INFORMATION 

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

 

Additional Resources:

Follow Dr Inder Paul Singh on social:
Dr Inder Paul Singh | LinkedIn

Follow Dr Arjan Hura on social:
Dr Arjan Hura | LinkedIn

Follow Dr Karolinne Rocha on social:
Dr Karolinne Rocha | LinkedIn

Peer2Peer educational platform:
https://rayner.com/peer2peer-omidria/

OMIDRIA HCP Portal:
https://www.omidriahcp.com/

 

US-OM-2300041 11/23

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This site is intended for US Physician educational purposes only, using scientific exchange around the OMIDRIA experience.

Rayner, the Rayner logo, OMIDRIA, the OMIDRIA logo, and OMIDRIAssure are proprietary marks of Rayner. ©2023 Rayner Group, all rights reserved. US-OM-2200071v4 11/23